Compare HUT & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUT | LGND |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | HUT | LGND |
|---|---|---|
| Price | $61.71 | $192.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 6 |
| Target Price | $54.29 | ★ $243.50 |
| AVG Volume (30 Days) | ★ 5.1M | 236.1K |
| Earning Date | 03-02-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | 1.89 | ★ 2.49 |
| Revenue | $178,318,000.00 | ★ $251,233,000.00 |
| Revenue This Year | $74.79 | $47.71 |
| Revenue Next Year | $116.78 | $9.77 |
| P/E Ratio | ★ $34.10 | $76.38 |
| Revenue Growth | 5.60 | ★ 64.83 |
| 52 Week Low | $10.04 | $93.58 |
| 52 Week High | $66.07 | $212.49 |
| Indicator | HUT | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 46.14 |
| Support Level | $53.26 | $188.13 |
| Resistance Level | $66.07 | $207.06 |
| Average True Range (ATR) | 5.01 | 8.38 |
| MACD | 0.03 | -0.75 |
| Stochastic Oscillator | 74.71 | 48.46 |
Hut 8 Corp is an energy infrastructure operator and Bitcoin miner with self-mining, hosting, managed services, and traditional data center operations across North America. The company has four reportable business segments: Power, Digital Infrastructure, Compute, and Other. It derives maximum revenue from the Compute segment which consists of Bitcoin Mining, GPU-as-a-Service, and Data Center Cloud operations. Its geographical segments include the United States and Canada, of which it generates the majority of revenue from the United States.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.